Form 4: Crinetics Pharmaceuticals Director Receives Significant Equity Compensation Package

Camille L. Bedrosian, a Director at Crinetics Pharmaceuticals, Inc., was granted 6,900 restricted stock units and 10,350 stock options as part of her compensation.

Summary

• Camille L. Bedrosian, a Director of Crinetics Pharmaceuticals, Inc. (CRNX), reported changes in her beneficial ownership of company securities.
• On June 11, 2025, Ms. Bedrosian acquired 6,900 shares of Common Stock in the form of restricted stock units (RSUs) at a price of $0 per share.
• These RSUs are set to vest 100% on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders, contingent on her continued service on the board.
• Following this transaction, Ms. Bedrosian beneficially owns 16,300 shares of Common Stock directly.
• Additionally, on June 11, 2025, she was granted 10,350 stock options with an exercise price of $32.33 per share.
• These stock options also vest on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders, subject to her continued board service.
• The stock options have an expiration date of June 11, 2035.
• After this transaction, Ms. Bedrosian beneficially owns 10,350 derivative securities (stock options) directly.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive as it reflects standard, expected compensation practices that align director interests with shareholders, without indicating any negative or unexpected events.

Positives

• The grant of restricted stock units and stock options aligns the director's financial interests with those of the shareholders, incentivizing long-term performance and value creation.
• Equity compensation is a standard practice for retaining and motivating experienced board members.

Future Outlook

The vesting schedules for both the restricted stock units and stock options indicate a forward-looking incentive structure, requiring continued service on the board for the equity to fully vest, aligning the director's future commitment with the company's performance.

Management Comments

• The filing was signed by Tobin Schilke, acting as attorney-in-fact for Camille L. Bedrosian.

Industry Context

The granting of restricted stock units and stock options to directors is a common and established practice across the biotechnology and pharmaceutical industries, serving as a key component of executive and board compensation packages to attract and retain talent and align interests with shareholders.

Comparison to Industry Standards

• The structure of equity grants, including vesting schedules tied to continued service, is consistent with standard compensation practices for non-employee directors in publicly traded companies within the biotechnology sector.
• While specific comparable companies or projects are not detailed in this Form 4, the use of RSUs and stock options for director compensation is a widely adopted mechanism across the industry to incentivize long-term commitment and performance, similar to practices observed at companies like BioNTech, Moderna, or Regeneron Pharmaceuticals, which frequently utilize equity-based compensation for their leadership.

Corporate Governance

Related Party Transactions

• The grant of restricted stock units and stock options to a director constitutes a related party transaction, as it involves the company providing compensation to a member of its board of directors.

Stakeholder Impact

• Shareholders: The equity grants align the director's financial incentives with shareholder value creation, potentially leading to more shareholder-friendly decisions.
• Employees: While not directly impacted, the compensation structure for leadership can indirectly influence overall company culture and compensation philosophy.

Next Steps

• The restricted stock units and stock options will vest according to their specified schedules, contingent on the director's continued service on the board.

Key Dates

Keywords

Crinetics Pharmaceuticals, CRNX, Form 4, Insider Transaction, Equity Grant, Restricted Stock Units, Stock Options, Director Compensation, Beneficial Ownership